Yangyin Yiqi Mixture Ameliorates Bleomycin-Induced Pulmonary Fibrosis in Rats through Inhibiting TGF-1/Smad Pathway and Epithelial to Mesenchymal Transition

被引:16
|
作者
Meng, Lihong [1 ]
Zhang, Xiaomei [2 ]
Wang, Hong [3 ,4 ]
Dong, Huan [1 ]
Gu, Xiaofeng [1 ]
Yu, Xiaolin [1 ]
Liu, Yushan [1 ]
机构
[1] Beijing Univ Chinese Med, 11 North 3rd Ring Rd, Beijing 100029, Peoples R China
[2] Beijing Univ Chinese Med, Dongfang Hosp, Dept Resp Med, 6 1st Dist Fangxingyuan, Beijing 100078, Peoples R China
[3] Shunyi Hosp, Beijing Chinese Med Hosp, 5 Zhanqian East St, Beijing 101300, Peoples R China
[4] Capital Med Univ, Beijing Chinese Med Hosp, Art Museum, 23 Houjie St, Beijing 100010, Peoples R China
关键词
MYOFIBROBLAST; ACTIVATION; MECHANISMS; RECEPTOR;
D O I
10.1155/2019/2710509
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Objective. The aim of the current study was to investigate the protective effect of Yangyin Yiqi Mixture (YYYQ) on Bleomycin-induced pulmonary fibrosis in rats based on TGF-1/Smad signal pathway and epithelial to mesenchymal transition (EMT). Methods. 120 Wistar rats were randomly divided into six groups: control group, BLM group, BLM + Pred group, BLM+YYYQ-L group, BLM+YYYQ-M group, and BLM+YYYQ-H group. Rats were given an intratracheal instillation of 3 mg/kg BLM to establish the pulmonary fibrosis model and followed by different dosages of YYYQ (11, 22, 44g/kg, via intragastric gavage) or prednisone soluble (4.2mg/kg, via intragastric gavage) or water. After 14 days and 28 days, tissue sections were stained with hematoxylin-eosin and Masson's trichrome to observe histopathological changes. Protein levels of TGF-1, CTGF, Interleukin 18, and hydroxyproline were detected by ELISA method, and mRNA expressions of TGF-1, TRI, TRII, Smad3, Smad7, -SMA, E-cadherin, laminin, and collagen I were detected by RT-PCR. Results. TGF-1, CTGF, Interleukin 18, and hydroxyproline levels and mRNA expression of TGF-1, TRI, TRII, Smad3, -SMA, laminin, and collagen I were significantly increased (p <0.01), while Smad7 and E-cadherin levels were significantly decreased in BLM group (p <0.01). YYYQ-M and YYYQ-H group had downregulated the TGF-1, CTGF, hydroxyproline contents, and mRNA expression of TGF-1, TRI, TRII, Smad3, -SMA, laminin, and collagen I and upregulated mRNA levels of Smad7 and E-cadherin significantly (p <0.01 or p <0.05). The result from the present study, which was also supported by histological evidence, suggested that YYYQ-M group and YYYQ-H group exhibited better treatment effect on Bleomycin-induced pulmonary fibrotic rats when compared to that of BLM + Pred group (p <0.01). Meanwhile, the effect of YYYQ, in three different dosages, on the level of interleukin 18 was not significant. Conclusion. These results showed that YYYQ has the potential of ameliorating the progression of pulmonary fibrosis, and the mechanism may be related to suppressing TGF-1/Smad signal pathway and EMT in BLM-induced pulmonary fibrosis of rats.
引用
收藏
页数:13
相关论文
共 50 条
  • [11] Silencing FHL2 inhibits bleomycin-induced pulmonary fibrosis through the TGF-β1/Smad signaling pathway
    Shi, Mengkun
    Cui, Huixia
    Shi, Jialun
    Mei, Yunqing
    EXPERIMENTAL CELL RESEARCH, 2023, 423 (02)
  • [12] Baricitinib Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice by Inhibiting TGF-β1 Signaling Pathway
    Gu, Songtao
    Liang, Jingjing
    Zhang, Jianwei
    Liu, Zhichao
    Miao, Yang
    Wei, Yuli
    Li, Shimeng
    Gu, Jinying
    Cui, Yunyao
    Xiao, Ting
    Li, Xiaohe
    Yang, Cheng
    MOLECULES, 2023, 28 (05):
  • [13] Astragaloside IV modulates TGF-β1-dependent epithelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis
    Qian, Weibin
    Cai, Xinrui
    Qian, Qiuhai
    Zhang, Wei
    Wang, Dongli
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2018, 22 (09) : 4354 - 4365
  • [14] Kangfuxin Oral Liquid Attenuates Bleomycin-Induced Pulmonary Fibrosis via the TGF-β1/Smad Pathway
    Yao, Huan
    Wei, Shujun
    Xiang, Yongjing
    Wu, Ziqiang
    Liu, Weiwei
    Wang, Baojia
    Li, Xueping
    Xu, Huan
    Zhao, Juan
    Gao, Yongxiang
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2019, 2019
  • [15] Sorafenib ameliorates bleomycin-induced pulmonary fibrosis: potential roles in the inhibition of epithelial-mesenchymal transition and fibroblast activation
    Chen, Y-L
    Zhang, X.
    Bai, J.
    Gai, L.
    Ye, X-L
    Zhang, L.
    Xu, Q.
    Zhang, Y-X
    Xu, L.
    Li, H-P
    Ding, X.
    CELL DEATH & DISEASE, 2013, 4 : e665 - e665
  • [16] Anlotinib attenuated bleomycin-induced pulmonary fibrosis via the TGF-β1 signalling pathway
    Ruan, Hao
    Lv, Ziwei
    Liu, Shuaishuai
    Zhang, Liang
    Huang, Kai
    Gao, Shaoyan
    Gan, Wenhua
    Liu, Xiaowei
    Zhang, Shanshan
    Helian, Kaiyue
    Li, Xiaohe
    Zhou, Honggang
    Yang, Cheng
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2020, 72 (01) : 44 - 55
  • [17] Inhibition of Raf1 ameliorates bleomycin-induced pulmonary fibrosis through attenuation of TGF-β1 signaling
    Li, Shuang
    Liu, Jia
    Tan, Jiangning
    Li, Lian
    Kaltreider, Mary J.
    Zhao, Jing
    Kass, Daniel J.
    Shang, Dong
    Zhao, Yutong
    AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2018, 315 (02) : L241 - L247
  • [18] Bryodulcosigenin attenuates bleomycin-induced pulmonary fibrosis via inhibiting AMPK-mediated mesenchymal epithelial transition and oxidative stress
    Ding, Yue
    Wang, Lei
    Liu, Bei
    Ren, Guoqing
    Okubo, Ryosuke
    Yu, Jing
    Zhang, Chaofeng
    PHYTOTHERAPY RESEARCH, 2022, 36 (10) : 3911 - 3923
  • [19] Resveratrol alleviates bleomycin-induced pulmonary fibrosis by inhibiting epithelial-mesenchymal transition and down-regulating TLR4/NF-ΚB and TGF-β1/smad3 signalling pathways in rats
    Wang, Lei
    Shao, Mei
    Jiang, Wei
    Huang, Yangfeng
    TISSUE & CELL, 2022, 79
  • [20] Polyporus Polysaccharide Ameliorates Bleomycin-Induced Pulmonary Fibrosis by Suppressing Myofibroblast Differentiation via TGF-β/Smad2/3 Pathway
    Jiang, Jintao
    Wang, Fang
    Luo, Aishu
    Lin, Shiyu
    Feng, Xiaoke
    Yan, Wei
    Shi, Yumeng
    Zhang, Qian
    Gu, Xin
    Cui, Guoliang
    Wang, Jianan
    Wang, Lei
    Zhang, Qiande
    Tan, Wenfeng
    FRONTIERS IN PHARMACOLOGY, 2020, 11